%0 Randomized Controlled Trial
%T Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block.
%A Zhang Y
%A Jiang Y
%A Lei Q
%A Li C
%A Jin S
%A Wang Q
%A Huang Y
%A Li Y
%A Hong Y
%A Wang S
%A Lin H
%A Li H
%A Ou Y
%A Zou X
%A Sun Q
%A Guo Q
%A Chen Z
%A Min S
%A Qi Y
%A Jie Q
%A Liu J
%A Liu B
%A Zhang W
%J Br J Anaesth
%V 132
%N 1
%D 2024 Jan 24
%M 38007377
%F 11.719
%R 10.1016/j.bja.2023.10.022
%X <B>BACKGROUND: </B>Preliminary clinical trials of adamgammadex, a new cyclodextrin-based selective reversal agent, have demonstrated its efficacy in reversing neuromuscular block by rocuronium.<BR><B>METHODS: </B>This multicentre, randomised, double-blind, positive-controlled, non-inferiority phase III clinical trial compared the efficacy and safety of adamgammadex and sugammadex. We randomised 310 subjects to receive adamgammadex (4 mg kg-1) or sugammadex (2 mg kg-1) at reappearance of the second twitch of the train-of-four (TOF), and standard safety data were collected.<BR><B>RESULTS: </B>For the primary outcome, the proportion of patients with TOF ratio ≥0.9 within 5 min was 98.7% in the adamgammadex group vs 100% in the sugammadex group, with a point estimate and 95% confidence interval (CI) of 1.3% (-4.6%, +1.3%); the lower limit was greater than the non-inferiority margin of -10%. For the key secondary outcome, the median (inter quartile range) time from the start of administration of adamgammadex or sugammadex to recovery of TOF ratio to 0.9 was 2.25 (1.75, 2.75) min and 1.75 (1.50, 2.00) min, respectively. The difference was 0.50 (95% CI: 0.25, 0.50); the upper limit was lower than the non-inferiority margin of 5 min. In addition, there were no inferior results observed in secondary outcomes. Adamgammadex had a lower incidence of adverse drug reactions compared with sugammadex (anaphylactic reaction, recurarisation, decreased heart rate, and laryngospasm; P=0.047).<BR><B>CONCLUSIONS: </B>Adamgammadex was non-inferior to sugammadex with a possible lower incidence of adverse drug reactions compared with sugammadex. Adamgammadex may have a potential advantage in terms of its overall risk-benefit profile.<BR><B>BACKGROUND: </B>Chinese Clinical Trial Registry, ChiCTR2000039525. Registered October 30, 2020. https://www.chictr.org.cn/showproj.html?proj=56825.